{
  "id": 14000213,
  "title": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?",
  "url": "https://urgent.news/2026/10/12/johnson-johnson-vs-pfizer-which-healthcare-stock-is-a-better-buy-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T16:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/10/12/johnson-johnson-vs-pfizer-which-healthcare-stock-is-a-better-buy-in-2026/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?",
        "url": "https://urgent.news/2026/10/12/johnson-johnson-vs-pfizer-which-healthcare-stock-is-a-better-buy-in-14001214",
        "published": "2026-10-12T16:20:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}